Why so cheapBecause the actual cash the company received per share was
less than 1.70 because the underwriters took a fee. The other
add on was Dr debt Cr equity. So only the additional shares that
may be taken up will add additional cash. And until we get the FDA
news we wait for the delays to get worked out. We spent another $25 million
in Q2 so cash in the bank over Q1 at present moment net of fees is another
$25 million as of today but not on June 30. HT